Previous 10 | Next 10 |
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointme...
2023-12-27 08:27:59 ET First Wave BioPharma FWBI +107% on plans to sell niclosamide program . Cingulate ( CING ) +89% . Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy . Jet.AI ( JTAI ) +38% . Cohe...
2023-12-14 12:28:56 ET Gainers: Freight Technologies ( FRGT ) +178% . TPI Composites ( TPIC ) +67% . TriSalus Life Sciences ( TLSI ) +35% . Codexis ( CDXS ) +33% . Canterbury Park Holding Corp ( CPHC ) +33% . Canaan ( CAN ...
2023-12-14 11:22:25 ET More on Reneo Pharmaceuticals Reneo: Mavodelpar Data Expected December Of 2023 Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop William Blair starts Reneo at outperform, cites mitochondrial disorders drug Seeking Alphaȁ...
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused...
2023-11-16 15:55:17 ET Summary Reneo Pharmaceuticals, Inc. results from the phase 2/3 STRIDE study, using mavodelpar for the treatment of patients with primary mitochondrial myopathies, are due to mtDNA, expected December of 2023. If primary endpoint of the STRIDE study is met, th...
2023-11-15 14:57:49 ET More on Reneo Pharmaceuticals Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop HC Wainwright starts Reneo at buy, sees possible 2025 launch for lead drug Seeking Alpha’s Quant Rating on Reneo Pharmaceuticals Historica...
Reneo Pharmaceuticals Inc. (RPHM) is expected to report $-0.6 for Q3 2023
2023-11-13 08:49:46 ET More on Reneo Pharmaceuticals Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop HC Wainwright starts Reneo at buy, sees possible 2025 launch for lead drug Seeking Alpha’s Quant Rating on Reneo Pharmaceuticals Historica...
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...